ClinicalTrials.gov
ClinicalTrials.gov Menu

Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02635269
Recruitment Status : Recruiting
First Posted : December 18, 2015
Last Update Posted : September 1, 2017
Sponsor:
Information provided by (Responsible Party):
Karen Lindhardt Madsen, Rigshospitalet, Denmark

Brief Summary:
This study aims to characterize the pathophysiological mechanisms of 21 different metabolic myopathies. The study will focus on exercise capacity and the metabolic derangement during exercise.

Condition or disease Intervention/treatment Phase
Metabolism, Inborn Errors Lipid Metabolism, Inborn Errors Carbohydrate Metabolism, Inborn Errors Long-Chain 3-Hydroxyacyl-CoA Dehydrogenase Deficiency Glycogenin-1 Deficiency (Glycogen Storage Disease Type XV) Carnitine Palmitoyl Transferase 2 Deficiency VLCAD Deficiency Medium-chain Acyl-CoA Dehydrogenase Deficiency Multiple Acyl-CoA Dehydrogenase Deficiency Carnitine Transporter Deficiency Neutral Lipid Storage Disease Glycogen Storage Disease Type II Glycogen Storage Disease Type III Glycogen Storage Disease Type IV Glycogen Storage Disease Type V Muscle Phosphofructokinase Deficiency Phosphoglucomutase 1 Deficiency Phosphoglycerate Mutase Deficiency Phosphoglycerate Kinase Deficiency Phosphorylase Kinase Deficiency Beta Enolase Deficiency Lactate Dehydrogenase Deficiency Glycogen Synthase Deficiency Other: Sugar Not Applicable

  Hide Detailed Description

Detailed Description:

Patients will be compared to a group of matched healthy control subjects (matched for age, gender, physical activity level and BMI) for comparison of the primary and secondary outcome measures.

Methods:

Each subject will go through 3 test days.

Test day 1:

  • International Physical Activity Questionnaire (IPAQ). The results will be used to match the patients to control subjects.
  • DEXA-scan. This is used to estimate the volume of distribution for stable isotope tracers.
  • Maximal oxidative capacity test (max-test). On a cycle ergometer, subjects will exercise for approximately 15 minutes with increasing resistance until exhaustion. The peak oxidative and workload capacities will be compared to the healthy controls and will be used to find the workload that corresponds to 55-65 % of VO2max used in the following exercise tests.
  • Blood samples. Samples will be drawn before exercise and at exhaustion and will be analyzed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 2:

•Long exercise test #1. The purpose of this test is to measure the total fat and sugar oxidation rates during exercise by using stable isotope tracers.

Subjects arrive at the laboratory after 3-9 hours of fasting. One IV-catheter is inserted in the cubital vein in one arm and another in a peripheral vein in the other hand. The stable isotope tracers will be given in the cubital vein as a constant infusion of solutions of:

  • [U-13C]-palmitate (0.0026 mg x kg-1 x min-1, after a priming bolus of 0.085 mg x kg-1 NaH13CO3)
  • [1,1,2,3,3-2H5]-glycerol (0.0049 mg x kg-1 x min-1 )
  • [6.6-2H2]-glucose (0.0728 mg x kg-1 x min-1 ) For two hours the subjects rests while receiving the infusions until the tracers have distributed in the body and reached a steady state. After the rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 55-65% of VO2max.

The heart rate is continuously measured during exercise, and every other minute the subject evaluates his/her degree of exertion (Rate of Perceived Exertion, RPE) on a Borg scale.

•Blood and breath samples From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn and samples of the expired breath are collected.The breath is analysed for 13CO2 -enrichment. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.

Test day 3:

•Long exercise test #2. The purpose of this test is to investigate exercise capacity and performance measured as HR, VO2 and RPE during prolonged exercise. To mimic the conditions for the working muscles in healthy persons who have an intact metabolism, the patients are given an infusion of a 10% glucose solution to maintain the blood sugar while exercising.

Subjects arrive at the laboratory after 3-9 hours fasting. After 2 hours of rest, the subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max, like they did on test day 2. This time the subjects are not given stable isotope tracers. 10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.

Assessments of heart rate, Rate of Perceived Exertion and blood sampling follow the same protocol as on test day 1, except no breath samples are taken and no analyses of stable isotopes are made, since the tracers are not used on test day 3.

  • Blood samples. From 20 minutes before exercise and every ten minutes until the end of exercise, blood samples are drawn. The blood is analysed for the plasma concentrations of glucose, lactate, ammonia, creatine kinase and myoglobin.
  • Muscle Biopsy At the end of test day 1 the investigators will perform a voluntary muscle biopsy.

Statistical Methods:

The investigators will use a paired t-test, two-tailed testing (or the corresponding non-parametric test, if the assumption of normality is not met). A p-value of < 0.05 will be considered significant. Results will be reported with Confidence Intervals of the difference in means. SigmaPlot version 11.0 (or a similar statistical program) will be used for statistical analysis.

No interim analyses will be made during the 4 days trial period. In the case, that a patient withdraws/is withdrawn, the obtained data from the completed tests will be included in the analyses. Raw data that is clearly and indisputably a result of an error in measurement will not be included (evaluated by the investigator). Missing or lost data will if possible be reassessed.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 128 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Fat and Sugar Metabolism During Exercise in Patients With Metabolic Myopathy
Study Start Date : January 2016
Estimated Primary Completion Date : August 2020
Estimated Study Completion Date : December 2020


Arm Intervention/treatment
Experimental: Sugar
The subjects exercise on the cycle-ergometer until exhaustion or for a maximum of 1 hour at an intensity that corresponds to 60-65% of VO2max.
Other: Sugar
10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
Other Name: 10 % glucose infusion




Primary Outcome Measures :
  1. Total fat oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute. [ Time Frame: Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation ]
    Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry.


Secondary Outcome Measures :
  1. Maximal oxidative capacity (mL*kg-1*minutes-1) [ Time Frame: Day 1 of participation ]
    Oxidative capacity is measured continuously during a maximum exercise test on the first day of the trial. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal oxidative capacity is the peak measure during the test.

  2. Endurance measured as minutes:seconds [ Time Frame: Day 2 and 4 of participation ]
    During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. The test will last for 1 hour or until exhaustion. Endurance will be defined as the total exercise duration.

  3. Heart rate (HR) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in beats per minute. [ Time Frame: During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. ]
    During 1 hour cycling at 55-65% of VO2max the heart rate is measured every 2 minuts.

  4. Oxygen consumption rate (VO2) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured in mL. [ Time Frame: During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. ]
    During 1 hour cycling at 55-65% of VO2max the oxygen consumption rate is continuously measured.

  5. Self-evaluated exertion (Rate of Perceived Exertion (RPE)) during prolonged exercise, with and without blood sugar maintained by an infusion of a 10% glucose solution. Measured using a Borg-scale (6-20). [ Time Frame: During 1 hour cycling test 1 and 1 hour cycling test 2 on day 2 and 4 of participation. ]
    During 1 hour cycling at 55-65% of VO2max the participant is asked to rate their exertion every 2 minutes.

  6. Maximal workload capacity. Measured in watt [ Time Frame: Day 1 of participation ]
    The participant will be cycling at incremental workload until exhaustion. The test lasts about 15 minutes (when the participant is fully exhausted). The maximal workload is the peak measure at the end of the test.

  7. Total glucose oxidation (rate of disappearance) during prolonged moderate intensity exercise. Measured as micro mol per kg per minute. [ Time Frame: Measured at at time (minutes) -120, -20, -10, 0, 10, 20, 30, 40, 50, 60. Zero is the indicatet start of 1 hour cycling test. Measured on day 2 of participation ]
    Measured using stable isotope technique ([U-13C]-palmitate, [1,1,2,3,3-2H5]-glycerol and [6.6-2H2]-glucose ) and indirect calorimetry.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   15 Years to 80 Years   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Men and women with genetically and/or biochemically verified LCHAD Deficiency
  • Healthy controls needs to be healthy to be included, evaluated by the investigator.

Exclusion Criteria:

  • Competing conditions at risk of compromising the results of the study.
  • Pregnancy or breastfeeding
  • Cardiac or pulmonary disease contraindicating peak exercise testing or strenuous exercise.
  • Inability to understand the purpose of the trial or corporate for the conduction of the experiments.
  • Veins that are too difficult to puncture for blood sampling or insertion of intravenous catheters, evaluated by the investigator
  • Moderate to severe muscle weakness, that prevents the subject completing 10 minutes of cycle-ergometry exercise at 60-70 % of VO2peak, evaluated by the investigator.
  • Participation in other trials that may interfere with the results.
  • Intake of medications that may interfere with the results or may compromise exercise performance, as evaluated by the investigators.
  • Donation of blood within 30 days prior to conduction of the tests on test day 1.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02635269


Contacts
Contact: Mads PG Stemmerik, BSc (+45)35456135 mads.peter.godtfeldt.stemmerik@regionh.dk
Contact: Karen L Madsen, MD (+45)35456126 ext L karen.lindhardt.madsen@regionh.dk

Locations
Denmark
Neuromuscular Research Unit, 3342 Recruiting
Copenhagen, Denmark, DK-2100
Sponsors and Collaborators
Rigshospitalet, Denmark
Investigators
Principal Investigator: Karen L Madsen, MD Neuromuscular Research Unit

Publications:
Responsible Party: Karen Lindhardt Madsen, MD, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT02635269     History of Changes
Other Study ID Numbers: Metabolic Myopathy
H-15015150 ( Other Identifier: De Videnskabsetiske Komiteer for Region Hovedstaden )
First Posted: December 18, 2015    Key Record Dates
Last Update Posted: September 1, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by Karen Lindhardt Madsen, Rigshospitalet, Denmark:
Ergometry
Stable isotope tracers

Additional relevant MeSH terms:
Muscular Diseases
Mitochondrial Myopathies
Muscular Disorders, Atrophic
Metabolic Diseases
Glycogen Storage Disease
Metabolism, Inborn Errors
Glycogen Storage Disease Type II
Lipid Metabolism, Inborn Errors
Ichthyosiform Erythroderma, Congenital
Lipidoses
Glycogen Storage Disease Type V
Glycogen Storage Disease Type III
Glycogen Storage Disease Type IV
Cardiomyopathies
Hyperammonemia
Carbohydrate Metabolism, Inborn Errors
Rhabdomyolysis
Anemia, Hemolytic, Congenital Nonspherocytic
Genetic Diseases, X-Linked
Kidney Diseases
Glycogen Storage Disease Type VII
Multiple Acyl Coenzyme A Dehydrogenase Deficiency
Genetic Diseases, Inborn
Lysosomal Storage Diseases, Nervous System
Brain Diseases, Metabolic, Inborn
Brain Diseases, Metabolic
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Lysosomal Storage Diseases